联环药业：公司获得2类改良新药临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of the new drug LH-2417, aimed at treating benign prostatic hyperplasia in men [1] Group 1 - The drug LH-2417 is classified as a type 2 modified new drug [1] - The clinical trial will focus on the initial treatment of symptoms associated with benign prostatic hyperplasia [1] - The company plans to commence clinical trials in the near future [1]